Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Assets (2016 - 2025)

Sangamo Therapeutics has reported Non-Current Assets over the past 16 years, most recently at $23.9 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $23.9 million for Q4 2025, down 52.12% from a year ago — trailing twelve months through Dec 2025 was $164.7 million (down 23.86% YoY), and the annual figure for FY2025 was $23.9 million, down 52.12%.
  • Non-Current Assets for Q4 2025 was $23.9 million at Sangamo Therapeutics, down from $44.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for SGMO hit a ceiling of $325.0 million in Q3 2021 and a floor of $23.9 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $118.8 million (2023), compared with a mean of $160.5 million.
  • Biggest five-year swings in Non-Current Assets: surged 30.68% in 2021 and later plummeted 72.92% in 2023.
  • Sangamo Therapeutics' Non-Current Assets stood at $323.2 million in 2021, then fell by 18.87% to $262.2 million in 2022, then plummeted by 72.92% to $71.0 million in 2023, then dropped by 29.65% to $49.9 million in 2024, then tumbled by 52.12% to $23.9 million in 2025.
  • The last three reported values for Non-Current Assets were $23.9 million (Q4 2025), $44.6 million (Q3 2025), and $47.7 million (Q2 2025) per Business Quant data.